Nanoparticles carry inhibitors that can trigger immune system to defeat brain cancer

Scientists at the University of Michigan's Roger Cancer Center are optimistic about the discovery of a small molecule that blocks a key pathway in brain tumo.

In collaboration with multiple labs, the team created a nanoparticle to contain the inhibitor, and the results were even better than expect.

Not only did the nanoparticles deliver the inhibitor to tumors in a mouse model where the drug successfully turned on the immune system to eliminate the cancer, but the process triggered immune memory so that the reappearing tumors were also eliminated— — This suggests that this potential new approach could not only treat brain tumors, but also prevent or delay tumor recurren.

"No one has been able to bring this molecule into the bra.

Study author Pedro.

Gliomas are often resistant to conventional therapies, and the environment inside the tumor suppresses the immune system, rendering new immune-based therapies ineffecti.

The Castro-Lowenstein lab saw an opportuni.

But AMD3100 had a hard time reaching the tum.

The Castro-Lowenstein lab, in collaboration with .

Castro also contacted Anuska.

The researchers injected nanoparticles loaded with amd3100 into mice with gliom.

"If you don't have blood flow, nothing will reach your go.

Further studies on mouse and patient cell lines showed that combining AMD3100 nanoparticles with radiation therapy was more effective than either nanoparticles or radiation alo.

In mice whose tumors were eliminated, the researchers simulated tumor recurrence by reimplanting the tumo.

"Every glioma recu.

Initial tests showed little or no effect on the mice's liver, kidney or heart function and normal blood counts after the treatme.

article title

Systemic delivery of an adjuvant CXCR4-CXCL-12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy